1. Why Blood Flow Matters in PBPK
Physiologically based pharmacokinetic (PBPK) models represent the body using compartments that correspond to physiological organs and tissues. Unlike classical compartmental models, a PBPK model explicitly incorporates quantities such as organ volumes, blood flows, tissue composition, and drug-specific properties.
Blood flow is central because the circulating blood connects organs throughout the body. After drug enters the systemic circulation, blood delivers drug to tissues, while tissues return drug to the venous circulation.
A PBPK model links systemic blood to individual organs and tissues. Each tissue can have its own physiological volume, blood flow, composition, and drug distribution properties.
2. Organ Blood Flow in a PBPK Model
Each organ receives a characteristic fraction of cardiac output. PBPK models use these physiological blood flows to determine the delivery of drug from the circulating blood to individual tissues.
If \(Q_i\) denotes blood flow to tissue \(i\), then the total tissue blood flow is related to cardiac output \(Q\) by:
In a simplified systemic model, the fraction of cardiac output directed to tissue \(i\) can be written as:
A highly perfused tissue therefore receives a large amount of blood per unit time, whereas a poorly perfused tissue receives less.
| Physiological characteristic | PBPK role |
|---|---|
| Cardiac output | Sets the overall systemic blood-flow scale. |
| Organ blood flow | Determines drug delivery from blood to a particular organ. |
| Tissue volume | Determines the physical size of the tissue compartment. |
| Blood composition | Influences the concentration of drug available for tissue distribution. |
| Tissue composition | Influences partitioning and the amount of drug associated with the tissue. |
Blood flow is therefore not simply another fitted parameter. In a mechanistic PBPK model, it is generally connected to physiological information about the organism and its organs.
3. Perfusion-Limited Tissue Distribution
One of the simplest ways to represent tissue distribution is the perfusion-limited or blood-flow-limited assumption.
Under this assumption, drug crosses between blood and tissue rapidly enough that the tissue is effectively close to its equilibrium relationship with blood. Blood flow then becomes an important determinant of how rapidly the tissue approaches its equilibrium concentration.
A simplified tissue mass-balance equation can be expressed as:
where:
- \(A_i\) is the amount of drug in tissue \(i\).
- \(Q_i\) is blood flow to tissue \(i\).
- \(C_B\) is the relevant blood concentration.
- \(C_i\) is the total tissue concentration.
- \(K_{p,i}\) is the tissue:blood partition coefficient.
The equation illustrates two separate ideas. Blood flow controls delivery, while partitioning controls the equilibrium relationship between tissue and blood.
4. Tissue:blood Partition Coefficients
The tissue:blood partition coefficient, commonly written \(K_p\), describes the equilibrium relationship between drug concentration in a tissue and drug concentration in blood.
If \(K_{p,i}=2\), then under the assumptions of the equilibrium model, the total concentration in tissue \(i\) is twice the blood concentration at equilibrium.
For a tissue with volume \(V_i\), the amount of drug associated with the tissue can be represented approximately as:
This equation demonstrates why both tissue volume and partition coefficient matter. A large tissue with a moderate \(K_p\) can contribute substantial drug mass to the overall distribution volume.
| \(K_p\) behavior | Interpretation at equilibrium |
|---|---|
| \(K_p<1\) | Tissue concentration is lower than blood concentration. |
| \(K_p=1\) | Tissue and blood concentrations are equal. |
| \(K_p>1\) | Tissue concentration exceeds blood concentration. |
| Very large \(K_p\) | The tissue can act as a substantial distribution reservoir. |
In mechanistic PBPK models, \(K_p\) values may be predicted from physicochemical properties, tissue composition, binding characteristics, or other mechanistic approaches rather than estimated independently from every clinical dataset.
5. Blood Flow Versus Tissue Partitioning
Blood flow and tissue partitioning answer different questions.
| Factor | Primary question | Effect on distribution |
|---|---|---|
| Blood flow \(Q\) | How rapidly is drug delivered? | Controls the rate of drug delivery and, in perfusion-limited models, the approach toward equilibrium. |
| Partition coefficient \(K_p\) | How does tissue concentration relate to blood concentration? | Controls the equilibrium extent of distribution. |
| Tissue volume \(V_T\) | How much physical tissue is present? | Contributes to the total amount of drug that can be stored in tissue. |
| Permeability | Can drug cross the tissue barrier rapidly? | Can become rate-limiting when membrane transport is slower than blood delivery. |
Consider two tissues. Tissue A receives a large blood flow but has a \(K_p\) near 1. Tissue B receives a smaller blood flow but has a very large \(K_p\). Tissue A may equilibrate rapidly, while Tissue B may ultimately contain much more drug.
This is one of the central insights of PBPK modeling: the rate and extent of distribution do not necessarily have the same determinant.
6. When Blood Flow Is Not Enough: Permeability-Limited Distribution
Not every tissue can be adequately represented by assuming instantaneous equilibration between blood and tissue. Biological barriers can restrict drug movement.
Examples include the blood-brain barrier, blood-testis barrier, and other specialized interfaces where endothelial properties, tight junctions, transporters, or membrane permeability can substantially influence distribution.
In a permeability-limited model, tissue distribution may depend on an effective permeability-surface area term, often represented as \(PS\).
Here \(C_{B,u}\) and \(C_{T,u}\) represent unbound concentrations, and \(K_{p,u}\) represents an unbound partition relationship.
The important conceptual difference is that the rate of distribution is now influenced by a transport capacity rather than being determined solely by blood flow.
7. A Simple Well-Stirred Tissue Model
For a perfusion-limited tissue, a common conceptual representation assumes that incoming arterial blood is instantaneously mixed with the tissue environment and leaves at the corresponding venous concentration.
Let \(C_A\) denote arterial concentration and \(C_V\) denote venous concentration. The tissue mass balance can be written as:
If the tissue rapidly approaches equilibrium with blood according to \(K_p\), then:
Combining these relationships allows the tissue concentration and amount to be linked to the incoming blood concentration, blood flow, and partition coefficient.
The exact formulation used in a PBPK implementation can differ depending on whether concentrations are expressed relative to whole blood, plasma, or unbound drug, and depending on the assumptions about tissue binding and blood-tissue exchange.
8. Well-Perfused and Poorly Perfused Tissues
PBPK models often distinguish tissues according to their relative blood supply.
| Characteristic | Well-perfused tissue | Poorly perfused tissue |
|---|---|---|
| Relative blood delivery | High | Low |
| Early distribution | Often rapid | Often slower |
| Approach to equilibrium | Can occur relatively quickly when exchange is not limiting | Can occur more slowly because delivery is slower |
| Examples often represented in PBPK | Liver, kidney, brain, heart | Adipose, muscle, skin and other tissues depending on physiological state |
These labels are relative rather than absolute. Physiological state, exercise, disease, temperature, age, and other factors can alter tissue perfusion.
The distinction is particularly important after an IV dose. Drug initially reaches highly perfused organs rapidly, while distribution into tissues with lower blood flow can occur on a slower time scale.
9. Blood Flow Shapes the Time Course of Distribution
Suppose two tissues have identical partition coefficients but different blood flows. The tissue receiving greater blood flow can generally approach its equilibrium concentration more rapidly under a perfusion-limited assumption.
Conceptual illustration: with the same equilibrium target, a higher-flow tissue can approach equilibrium more rapidly under a perfusion-limited assumption.
This does not mean that blood flow determines the final tissue concentration by itself. If the two tissues have different \(K_p\) values, their equilibrium concentrations can differ substantially even if they receive similar blood flow.
10. Why Unbound Drug Matters
Drug molecules in blood may be bound to plasma proteins, while drug in tissues may interact with proteins, lipids, phospholipids, or other tissue components.
For many mechanistic PBPK applications, the unbound fraction is important because unbound drug is generally the fraction available for passive diffusion and many pharmacological processes.
Let \(f_{u,B}\) denote the unbound fraction in blood and \(f_{u,T}\) the unbound fraction in tissue. A simplified unbound partition coefficient can be related conceptually to total partitioning through these binding properties.
The distinction between total and unbound concentrations becomes particularly important when plasma protein binding or tissue binding is substantial.
11. What Physiological Inputs Does a PBPK Model Need?
A PBPK model combines physiological information with drug-specific properties. For tissue distribution, several physiological quantities are particularly important.
| Input | Role in tissue distribution |
|---|---|
| Organ volume | Defines the physical size of the tissue compartment. |
| Organ blood flow | Controls delivery of drug from blood to the tissue. |
| Cardiac output | Provides the systemic blood-flow constraint. |
| Tissue composition | Contributes to partitioning based on water, lipid, protein and other components. |
| Plasma protein binding | Influences the fraction of drug that remains unbound in blood. |
| Tissue binding | Influences the amount of drug associated with tissue components. |
| Permeability and surface area | Can determine whether membrane transport limits distribution. |
These inputs allow PBPK models to make tissue-level predictions rather than treating distribution as a single empirical volume parameter.
12. Drug Properties That Influence Tissue Distribution
Physiology alone is not sufficient. The distribution of a particular compound depends on its physicochemical and binding properties.
- Lipophilicity: influences affinity for lipid-rich tissues and biological membranes.
- Ionization: affects membrane permeability and distribution according to the physicochemical environment.
- Molecular size: can influence passive permeability and transport.
- Plasma protein binding: influences the concentration of unbound drug available for distribution.
- Tissue binding: can increase tissue retention and apparent distribution volume.
- Transporter interactions: active uptake or efflux can alter distribution in specific organs.
- pH-dependent partitioning: can influence tissue accumulation for ionizable compounds.
PBPK modeling is powerful because these drug properties can be combined with physiological characteristics to predict distribution across multiple tissues simultaneously.
13. The Liver: Distribution and Elimination
The liver illustrates why distribution and elimination cannot always be considered separately.
Hepatic blood flow determines how much drug is delivered to the liver per unit time. Once drug reaches the liver, uptake, intracellular distribution, metabolism, biliary excretion, and transport processes can determine what happens next.
A simplified hepatic extraction concept can be represented as:
where \(CL_H\) is hepatic clearance, \(Q_H\) is hepatic blood flow, and \(E_H\) is the hepatic extraction ratio.
Thus, hepatic blood flow can influence systemic clearance for compounds with substantial hepatic extraction, while the same organ is also a major tissue compartment in which drug can distribute.
14. The Brain and Other Barrier-Limited Tissues
The brain is an important example of why tissue blood flow alone does not determine tissue exposure.
The brain receives substantial blood flow, but drug movement from blood into brain tissue is constrained by the blood-brain barrier. Passive permeability, active uptake, active efflux, and binding can all influence brain exposure.
Consequently, two drugs with similar systemic concentrations can produce very different brain concentrations.
A PBPK model can represent this situation by including explicit permeability or transporter terms rather than assuming immediate equilibration between plasma and brain.
This distinction is especially important when the scientific question concerns site-of-action exposure rather than simply plasma exposure.
15. From Individual Tissues to the Whole Body
A PBPK model combines individual tissue compartments into a connected physiological system.
where \(A_B\) represents drug amount in blood and \(A_i\) represents drug amount in tissue \(i\).
If tissue concentrations are represented using equilibrium partition coefficients, the total amount can be expressed conceptually as:
This relationship illustrates how a PBPK model can produce an apparent whole-body distribution volume from the individual properties of many tissues.
The model therefore replaces a single empirical distribution parameter with a structured collection of physiological and drug-specific quantities.
16. Worked Example: How Blood Flow and \(K_p\) Affect Tissue Distribution
Consider a hypothetical drug administered intravenously. Assume that the systemic blood concentration is initially:
Consider two tissues:
| Quantity | Tissue A | Tissue B |
|---|---|---|
| Blood flow | 1.0 L/min | 0.2 L/min |
| Tissue volume | 5 L | 10 L |
| \(K_p\) | 0.5 | 4.0 |
Step 1: Equilibrium concentration
For Tissue A:
For Tissue B:
Step 2: Tissue drug amount
For Tissue A:
For Tissue B:
Step 3: Interpretation
Tissue A receives five times as much blood flow as Tissue B, but Tissue B has a much larger \(K_p\) and a larger tissue volume. Consequently, Tissue B can contain substantially more drug at equilibrium despite receiving less blood flow.
17. What Happens When a PBPK Input Changes?
One advantage of PBPK models is that individual physiological and drug-specific assumptions can be changed to examine their consequences.
| Change | Potential consequence |
|---|---|
| Increase tissue blood flow | Faster delivery and potentially faster approach to distribution equilibrium under perfusion-limited conditions. |
| Increase \(K_p\) | Higher equilibrium tissue concentration relative to blood. |
| Increase tissue volume | Greater potential tissue drug mass at a given tissue concentration. |
| Decrease permeability | Slower tissue distribution when membrane transport is rate-limiting. |
| Increase tissue binding | Potentially greater tissue retention and altered unbound tissue concentration. |
| Alter plasma protein binding | Can change the unbound concentration available for distribution and elimination. |
Sensitivity analysis can therefore help determine which physiological or drug-specific assumptions have the greatest influence on predicted tissue exposure.
18. Why Disease and Patient Characteristics Matter
Physiology is not constant across all individuals or clinical conditions. PBPK models can incorporate changes in physiological characteristics when those changes are supported by appropriate data.
Examples include:
- Changes in organ blood flow.
- Changes in organ size or tissue volume.
- Changes in plasma protein concentrations.
- Changes in renal or hepatic function.
- Changes in tissue composition.
- Changes in transporter or enzyme activity.
- Changes associated with age, pregnancy, body size, or disease.
This capability is one reason PBPK models are useful for exploring populations or physiological conditions in which direct clinical PK observations may be limited.
19. Building Tissue Distribution Into a PBPK Model
A practical PBPK workflow for tissue distribution can be organized into several steps.
- Define the physiological system. Identify the organs and tissues needed to answer the scientific question.
- Specify tissue volumes. Assign physiological volumes to each compartment.
- Specify blood flows. Establish organ blood flows consistent with the physiological population being modeled.
- Characterize drug binding. Determine relevant plasma and tissue binding properties.
- Estimate or predict partition coefficients. Assign appropriate tissue:blood or tissue:plasma partition relationships.
- Determine whether distribution is perfusion- or permeability-limited. Use biological knowledge and available data to determine whether a simple equilibrium assumption is adequate.
- Add organ-specific mechanisms. Include transporters, metabolism, sequestration, or other processes where scientifically justified.
- Evaluate predictions. Compare predicted plasma and, where available, tissue concentrations with observations.
The objective is not to include every conceivable biological process. The objective is to include enough mechanistic detail to answer the intended question reliably.
20. What Tissue Concentrations Does a PBPK Model Actually Predict?
PBPK predictions can represent several different quantities, and these should not be treated as interchangeable.
| Quantity | Meaning |
|---|---|
| Total tissue concentration | Concentration including bound and unbound drug according to the model definition. |
| Unbound tissue concentration | Concentration of drug not bound within the tissue environment. |
| Tissue drug amount | Total amount associated with a tissue compartment. |
| Blood concentration | Drug concentration in circulating blood. |
| Plasma concentration | Drug concentration measured in plasma. |
| Site-of-action concentration | Concentration at a biological location relevant to pharmacologic effect. |
The distinction matters because a high total tissue concentration does not necessarily imply a high pharmacologically active unbound concentration.
21. What Blood-Flow-Based PBPK Models Do Not Tell Us Automatically
Mechanistic structure does not eliminate uncertainty. Several limitations should be considered when interpreting tissue-distribution predictions.
- Physiological inputs are estimates. Organ volumes and blood flows vary between individuals.
- Partition coefficients can be uncertain. Predicted \(K_p\) values depend on assumptions and available drug-specific information.
- Equilibrium assumptions may fail. Some tissues have barriers or transport processes that make distribution permeability-limited.
- Binding assumptions matter. Errors in plasma or tissue binding can propagate into predicted tissue exposure.
- Transporters can be important. Passive diffusion alone may not describe distribution for transporter substrates.
- Validation data may be sparse. Plasma concentrations are often much easier to measure than concentrations in human tissues.
- Predictions remain model-dependent. A mechanistic model is still a model and therefore depends on its assumptions.
22. Why Tissue Distribution Matters in Drug Development
Blood flow and tissue distribution are relevant whenever the concentration at a particular biological site matters.
- Central nervous system exposure: understanding penetration into brain tissue.
- Drug-drug interactions: evaluating changes in exposure when enzymes or transporters are inhibited or induced.
- Organ impairment: evaluating how altered physiology may affect systemic and tissue exposure.
- Special populations: incorporating physiological differences associated with age, body size, pregnancy, or other characteristics.
- Target-site exposure: relating predicted tissue concentrations to pharmacologic activity.
- Toxicology: exploring tissue exposure when direct measurement is limited.
- Dose selection: connecting systemic dosing to predicted exposure at relevant tissues.
These applications illustrate why PBPK is more than a mathematical description of plasma concentration. Its purpose is to connect dose and systemic exposure with the underlying physiological system.
23. From Blood Flow to Site-of-Action Exposure
The ultimate reason to understand tissue distribution is often pharmacologic effect.
For a drug whose target is located in a specific tissue, plasma concentration may not be the most direct exposure measure. A PBPK model can provide a mechanistic link between systemic concentration and predicted tissue concentration.
That tissue concentration can then be connected to a pharmacodynamic model. For example:
where \(C_T\) represents the relevant tissue concentration.
The result is a mechanistic chain connecting administration, circulation, tissue distribution, and pharmacologic response.
24. A Practical Workflow for Evaluating PBPK Tissue Distribution
- Define the tissue of interest. Determine whether the scientific question concerns systemic exposure or exposure at a particular organ or site.
- Characterize physiology. Establish tissue volume, blood flow, and relevant physiological characteristics.
- Characterize the drug. Determine physicochemical properties, protein binding, permeability, and transporter interactions as appropriate.
- Choose a distribution model. Decide whether perfusion-limited or permeability-limited representation is appropriate.
- Specify partitioning. Determine tissue:blood or tissue:plasma relationships.
- Connect tissues through circulation. Ensure that blood flows and mass balances are physiologically consistent.
- Simulate concentration-time profiles. Examine both plasma and predicted tissue concentrations.
- Perform sensitivity analysis. Identify inputs that materially influence tissue exposure.
- Compare with available observations. Use clinical, preclinical, imaging, biopsy, or other relevant evidence where available.
- Interpret cautiously. Distinguish measured concentrations from model-predicted tissue exposure.
25. Key Takeaways
- Blood flow is a fundamental physiological determinant of drug delivery to tissues in PBPK models.
- Organ blood flow determines how rapidly drug is delivered from the circulating blood to a tissue.
- Tissue:blood partition coefficients describe the equilibrium relationship between tissue and blood concentrations.
- Blood flow and \(K_p\) have different roles: blood flow primarily influences the rate of distribution, while \(K_p\) influences the extent of distribution.
- Tissue volume determines how much drug can be associated with a tissue at a given tissue concentration.
- Perfusion-limited models assume that blood-tissue exchange is sufficiently rapid relative to blood delivery.
- Permeability-limited models are useful when biological barriers or membrane transport make tissue exchange rate-limiting.
- Plasma protein binding and tissue binding influence unbound concentrations and therefore can materially affect distribution predictions.
- The liver illustrates how an organ can simultaneously serve as a distribution compartment and a site of drug elimination.
- The brain demonstrates why high blood flow does not necessarily imply high tissue exposure when a biological barrier limits drug entry.
- PBPK models combine physiological quantities with drug-specific properties to predict tissue concentrations and drug amounts.
- Tissue exposure predictions are conditional on physiological assumptions, partitioning estimates, permeability assumptions, and validation data.
- The most useful PBPK distribution model is one that contains sufficient mechanistic detail to answer the scientific question without adding unsupported complexity.
Where to Go Next
A natural next step is to study tissue partition coefficients in PBPK models in greater detail, including how \(K_p\) values can be predicted from drug lipophilicity, ionization, plasma protein binding, tissue composition, and other physicochemical properties.
From there, the concepts of blood flow and tissue partitioning can be extended to permeability-limited distribution, transporter-mediated tissue uptake, the blood-brain barrier, and organ-specific PBPK models.
References
- Jones HM, Rowland-Yeo K. Basic concepts in physiologically based pharmacokinetic modeling in drug discovery and development. CPT: Pharmacometrics & Systems Pharmacology. 2013;2:e63.
- Edginton AN, Willmann S. Physiology-based pharmacokinetic modeling and simulation. Clinical Pharmacology & Therapeutics.
- Pang KS, Rowland M. Hepatic clearance of drugs. I. Theoretical considerations of a "well-stirred" model and a parallel tube model. Journal of Pharmacokinetics and Biopharmaceutics.
- Rowland M, Tozer TN. Clinical Pharmacokinetics and Pharmacodynamics: Concepts and Applications. Wolters Kluwer.
- Berezhkovskiy LM. The corrected equilibrium partition coefficient for a drug between plasma and tissues in pharmacokinetic modeling. Journal of Pharmacokinetics and Pharmacodynamics.